Tyrosine-kinases inhibitors in recurrent platinum-resistant ovarian cancer patients
详细信息 查看全文
- 作者：C. Marchettia ; 1 ; clamarchetti@libero.it" class="auth_mail" title="E-mail the corresponding author ; I. Palaiaa ; 1 ; innocenza.palai@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; F. De Feliceb ; fradefelice@hotmail.it" class="auth_mail" title="E-mail the corresponding author ; A. Musellaa ; 1 ; angela.musell@gmail.com" class="auth_mail" title="E-mail the corresponding author ; C. Donfracescoa ; 1 ; cristina.donfancesco@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; L. Vertechya ; 1 ; lauravertecy@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; A. Romitoa ; 1 ; alessia.romto@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; I. Piacentia ; 1 ; ilarapiacenti@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; D. Musiob ; 2 ; danela.musio@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; L. Muziia ; 1 ; ludovic.muzi@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; V. Tombolinib ; 2 ; vincenzo.tombolni@uniroma1.it" class="auth_mail" title="E-mail the corresponding author ; P. Benedetti Panicia ; 1 ; pierluigi.benedettpanici@uniroma1.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Ovarian cancer ; Platinum resistant ; Recurrence ; Gynecologic ; Tyrosine-kinases inhibitors
- 刊名：Cancer Treatment Reviews
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：42
- 期：Complete
- 页码：41-46
- 全文大小：293 K
文摘
- •
The risk of recurrence in ovarian cancer (OC) represents a common entity.
- •
The role of tyrosine-kinases inhibitors (TKI) in recurrent OC needs to be clarified.
- •
This is the largest reported analysis of published data.
- •
This analysis suggests that TKI could be considered a valid option in recurrent OC.